Results 21 to 30 of about 993 (163)

Salvage Therapy with Rezafungin for Candida parapsilosis Spondylodiscitis: A Case Report from Expanded Access Program

Microorganisms
Candida spp. spondylodiscitis is a rare condition for which treatment options are often limited. A further obstacle is the duration of therapy, which should be administered for up to twelve months.
Giulio Viceconte, Antonio Riccardo Buonomo, Nunzia Esposito, Letizia Cattaneo, Teresa Somma, Maria Michela Scirocco, Ciro Gabriele Mainolfi, Ivan Gentile   +7 more
doaj   +3 more sources

Salvage therapy of complicated Candida albicans spondylodiscitis with Rezafungin

European Journal of Clinical Microbiology & Infectious Diseases
Invasive fungal infections, particularly those caused by Candida species, represent an increasing cause of hospital-related morbidity and mortality. Most commonly Candida spp. is the causative agent of candidemia and invasive candidiasis. In this report we present a complex case of Candida albicans spondylodiscitis, successfully treated with rezafungin,
Grasselli Kmet, Nina, Luzzati, Roberto, Monticelli, Jacopo, Babich, Stella, Conti, Jacopo, Bella, Stefano Di   +5 more
openaire   +4 more sources

Anidulafungin is a useful surrogate marker for predicting in vitro susceptibility to rezafungin among five Candida species using CLSI methods and interpretive criteria [PDF]

Journal of Clinical Microbiology
This study addresses the use of other echinocandins as surrogate markers to predict the susceptibility of rezafungin against the six most common Candida spp.
Marisa L. Winkler, Lalitagauri Deshpande, John H. Kimbrough, Maura Karr, Paul Rhomberg, Abby L. Klauer, Mariana Castanheira   +6 more
doaj   +2 more sources

Necrotizing gingival infection due to in an hematopoietic stem cell transplant recipient: case report [PDF]

Therapeutic Advances in Infectious Disease
Trichoderma is a genus of rare filamentous fungi that can cause invasive fungal infections in immunocompromised patients. We report a case of necrotizing gingival and sinus infection due to T.
Eduardo Aparicio-Minguijón, Nieves López-Muñoz, Pilar Martínez-Sánchez, María Calbacho, Ana Pérez-Ayala, Justino Jiménez-Almonacid, María Asunción Pérez-Jacoiste Asín, Isabel Rodríguez-Goncer   +7 more
doaj   +2 more sources

Long-term Safety and Effectiveness of Rezafungin Treatment in Candidemia and Invasive Candidiasis: Results From an Early Access Program in Italy and Germany [PDF]

Open Forum Infectious Diseases
Outcomes are reported for 6 adults receiving rezafungin for chronic, hard-to-treat, invasive candidiasis (including Candida parapsilosis) during an early access program.
Elham Khatamzas, Giusy Tiseo, Giulio Viceconte   +2 more
exaly   +3 more sources

Multicentre determination of rezafungin (CD101) susceptibility of Candida species by the EUCAST method [PDF]

Clinical Microbiology and Infection, 2018
Rezafungin (CD101) is a new long-acting echinocandin allowing weekly dosing, currently undergoing phase-II clinical trials for invasive candidiasis. The aim of this study was to assess rezafungin's in vitro activity against the most frequent Candida species following the EUCAST methodology.The susceptibility of 2018 clinical Candida isolates was ...
Arendrup, M. C., Meletiadis, J., Zaragoza, O., Jørgensen, K. M., Marcos-Zambrano, L. J., Kanioura, L., Cuenca-Estrella, M., Mouton, J. W., Guinea, J.   +8 more
core   +6 more sources

Multicenter surveillance of antifungal susceptibility of clinical Aspergillus isolates to conventional and novel antifungal agents in Taiwan, 2021–2023 [PDF]

Microbiology Spectrum
Periodic surveillance of antifungal susceptibility among Aspergillus isolates is essential to guide effective treatment. This multicenter study analyzed 550 clinical Aspergillus isolates collected in Taiwan from 2021 to 2023, primarily from the ...
Ming-I Hsieh, Pui-Ching Choi, Wan-Lin Wu, Yu-Fu Lin, Chi-Jung Wu   +4 more
doaj   +2 more sources

In Vivo Efficacy of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in a Neutropenic Mouse Bloodstream Infection Model

Journal of Fungi
Objectives: Rezafungin is the first new drug approved to treat candidaemia and invasive candidiasis in more than 10 years. However, data are scant on the in vivo efficacy of rezafungin and the other three approved echinocandins against different Candida ...
Dávid Balázsi, Zoltán Tóth, Jeffrey B. Locke, Andrew M. Borman, Lajos Forgács, Noémi Balla, Fruzsina Kovács, Renátó Kovács, Chiaki Amano, Tugba Ilay Baran, László Majoros   +10 more
doaj   +2 more sources

Management of invasive candidiasis: A focus on rezafungin, ibrexafungerp, and fosmanogepix

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
AbstractManagement of invasive fungal infections is challenging with growing antifungal resistance. Broad antifungal use has resulted in greater intrinsic and acquired resistance among Candida spp. It is important for clinicians to recognize the relationship between host susceptibility, site of infection, Candida resistance profiles, specific drug ...
Benjamin A. August, Pramodini B. Kale‐Pradhan   +1 more
core   +4 more sources

Real-world experience with rezafungin for the treatment of biofilm-forming Candida infections

Future Microbiology
Biofilm eradication remains a significant challenge in clinical practice and contributes substantially to healthcare costs. Medical devices serve as a common substrate for biofilm formation and are implicated in a considerable proportion of invasive candidiasis cases.
Marta Albanell-Fernández, Álex Soriano, Sabina Herrera, Montse Tuset, Natalia Arranz, Corentin Deckers, Patrick M Honoré   +6 more
openaire   +4 more sources